Chronic pain is a widespread and costly health crisis affecting people globally. It is a leading cause of disability, mental health disorders, and opioid dependence, with an annual economic impact of approximately $560 billion in the U.S. Despite its prevalence, effective non-opioid pain management options remain scarce, and the overuse of opioids has contributed to addiction and overdose deaths. This underscores the urgent need for safer, non-addictive treatments. Acute pain, if not properly managed, can transition into chronic pain, increasing the likelihood of long-term opioid use. Studies show that up to 20% of patients with severe acute pain develop chronic pain, while opioid use after surgery can lead to dependence. Suzetrigine (VX-548), a novel NaV1.8 inhibitor, has emerged as a promising alternative, effectively reducing pain without opioid receptor activation. Clinical trials indicate its high selectivity, minimal side effects, and no risk of addiction. Addressing the chronic pain epidemic requires a shift toward non-opioid solutions. Expedited clinical trials, expanded research, improved insurance coverage, and education for healthcare providers and patients will be critical in ensuring broader access to safer and more effective pain management strategies.

The Chronic Pain Epidemic: A Growing Crisis
Chronic pain is one of the most prevalent and costly health conditions in the United States and worldwide. According to the CDC, over 51 million adults in the U.S. suffer from chronic pain, with 17.1 million experiencing high-impact chronic pain that severely limits daily activities.[1-3] Chronic pain is now recognized as a disease itself, leading to long-term disability, mental health disorders, and opioid dependence.

Globally, chronic pain affects over 1.5 billion people, with low back pain ranking as the leading cause of disability worldwide.[4] The economic burden in the U.S. is staggering, costing an estimated $560 billion annually in direct healthcare expenses, lost productivity, and disability benefits. The personal toll is equally devastating—chronic pain leads to job loss, financial hardship, and deteriorating mental health, contributing to higher rates of depression, anxiety, and opioid addiction.[5-7]

Despite these overwhelming statistics, effective non-opioid pain management options remain limited. The opioid epidemic, fueled in part by the overprescription of painkillers, has claimed over 600,000 lives in the U.S. since 1999.[8,9] This crisis underscores the urgent need for safer, non-addictive pharmacologic solutions that can effectively manage pain without fueling addiction.

The Link Between Acute Pain and Chronic Pain: The Role of Opioids
Acute pain, if not managed effectively, can transition into chronic pain, a phenomenon known as “pain chronification.” Studies suggest that up to 20% of patients who experience severe acute pain after surgery or trauma will develop chronic pain.[10] This transition occurs due to persistent inflammation, changes in neural plasticity, and prolonged sensitization of pain pathways in both the central and peripheral nervous systems.[11] Effective early pain management using multimodal strategies, including non-opioid medications, can significantly reduce the risk of developing chronic pain conditions.

Initial opioid exposure following surgery or acute pain episodes poses a significant risk for long-term opioid use and dependence. Research indicates that about 6% of patients prescribed opioids for postoperative pain continue using them beyond 90 days, with some developing opioid use disorder.[12] Furthermore, prolonged opioid use after surgery is associated with a higher likelihood of opioid addiction, particularly in opioid-naïve patients. This underscores the urgent need for non-opioid alternatives such as suzetrigine to reduce the risk of opioid dependence while effectively managing acute and chronic pain.[13]

Suzetrigine: A Promising Advancement in Pain Medicine
A groundbreaking study, ‘Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain,’ presents suzetrigine (VX-548) as a novel, non-opioid pain medication with a unique mechanism of action.[5] Unlike opioids, which act on the central nervous system and pose a high risk of addiction and overdose, suzetrigine selectively inhibits the NaV1.8 voltage-gated sodium channel, which is specific to peripheral pain-sensing neurons and absent in the central nervous system.[5]

Clinical trials confirm that suzetrigine:

• Effectively reduces pain without engaging opioid receptors.
• Has high selectivity (≥31,000-fold for NaV1.8 over other NaV subtypes), minimizing off-target effects.
• Demonstrates no CNS side effects, no evidence of dependence or addiction, and no cardiovascular risks.[5]

Given these promising results, suzetrigine could be a game-changing alternative to opioids, offering effective pain relief without the devastating consequences of addiction.

Future Directions: Integrating Non-Opioid Solutions
The introduction of suzetrigine aligns with a broader push toward non-opioid pain management strategies. However, its success will depend on several critical factors:

Expedited clinical trials and FDA approval: Given the urgency of the opioid crisis, regulatory bodies must prioritize fast-tracking non-opioid pain treatments like suzetrigine. Large-scale Phase 3 trials are necessary to confirm its long-term safety and efficacy.[6]

Expanded indications beyond neuropathic pain: Chronic pain conditions such as low back pain, cancer pain, and fibromyalgia are among the most debilitating and costly to society. Research should explore whether suzetrigine can be combined with neuromodulation, peripheral nerve stimulation, and regenerative medicine to enhance overall pain control.[7]

Insurance coverage and accessibility: Many promising non-opioid treatments fail due to a lack of insurance coverage, leaving patients with few alternatives to opioids. Policymakers must work with payers to ensure affordability and access to non-addictive pain treatments, particularly in underserved rural and economically disadvantaged regions, where opioid overprescription remains rampant.[8]

Education for prescribers and patients: Opioids became a first-line treatment for chronic pain due to aggressive marketing and a lack of awareness about alternative options. Clinicians must be educated about new non-opioid pain management tools, and patients must be made aware that effective pain relief does not require opioid therapy.[9]

The opioid epidemic has forced a reckoning in pain management. Suzetrigine represents a significant step forward, offering a non-addictive, effective alternative for chronic pain sufferers.[5] However, innovation alone is not enough. A multifaceted approach that combines research, policy changes, and education is necessary to ensure equitable access to safer pain treatments.[5]

Chronic pain is not just a personal struggle—it is a public health crisis with profound economic and social consequences. If we are to combat opioid misuse effectively, we must embrace novel pain management solutions and redefine how we treat pain in the 21st century. Suzetrigine and similar breakthroughs could lead us toward an opioid-free future—one where pain relief does not come at the cost of addiction and devastation.[5]

Not reported

Not applicable

Suresh Srinivasan
Department of Anesthesiology
Trinity Health System, Steubenville, OH 43952, United States
Email: Suresh.Srinivasan@commonspirit.org

The author contributed to the conceptualization, investigation, and data curation by acquiring and critically reviewing the selected articles and was involved in the Writing – original draft preparation and writing – review & editing to refine the manuscript.

Not applicable

The authors declare no conflict of interest.

None

https://doi.org/10.63096/medtigo3067115

Suresh S. Suzetrigine and the Future of Non-Addictive Pain Management in the Midst of the U.S. Opioid Epidemic. medtigo J Anesth Pain Med. 2025;1(1):e3067115. doi:10.63096/medtigo3067115 Crossref